On June 8, the U.S. Food and Drug Administration (FDA) approved Perjeta (pertuzumab), a new anti-HER2 therapy, to treat patients with HER2-positive late-stage breast cancer. Read more.
AmericanNurseToday.com is dedicated to integrating the art and science of nursing by providing an interactive destination for nurses to enhance their personal and professional development. The site features timely nursing research news, clinical and practice updates, drug information, continuing education, web exclusive editorial, a nursing community, and much more. Participate in our blogs to interact with your colleagues and find out what they’re saying about today’s hottest topics from the print journal. Leave a comment on open access articles, send a letter to the editor, or email us your comments. American Nurse Today is the official journal of the American Nurses Association, and continues to serve as an influential voice for nurses across the country.
evidence based practice quality improvement in clinical setting | why nurses cross the boundary? | why nurses cross the boundary | where is nursing going in the future | drug seeking patient in the ed | cancer diet | nursing peer evaluation | helping | high potassium | articles on nursing theories
Copyright© 2013 by HealthCom Media. All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder.